If the FDA sticks to its deadline, Neos Therapeutics Inc. (NEOS) will get to know the future of NT-0202, its product candidate for the treatment of attention deficit hyperactivity disorder, or ADHD, later today.
Forex – financial instrument.Forex news
If the FDA sticks to its deadline, Neos Therapeutics Inc. (NEOS) will get to know the future of NT-0202, its product candidate for the treatment of attention deficit hyperactivity disorder, or ADHD, later today.